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Surfactant protein-D (SP-D), a member of the collectin family has been shown to induce
apoptosis in cancer cells. SP-D is composed of an N-terminal collagen-like domain and a
calcium-dependent carbohydrate recognition domain (CRD). Recently, we reported that a
recombinant fragment of human SP-D (rfhSP-D), composed of homotrimeric CRD region,
induced intrinsic apoptotic pathway in prostate cancer cells. Here, we analyzed the
membrane interactome of rfhSP-D in an androgen-independent prostate cancer cell line,
PC3, by high resolution mass spectrometry and identified 347 proteins. Computational
analysis of PPI network of this interactome in the context of prostate cancer metastasis
and apoptosis revealed Glucose Regulated Protein of 78 kDa (GRP78) as an important
binding partner of rfhSP-D. Docking studies suggested that rfhSP-D (CRD) bound to the
substrate-binding domain of glycosylated GRP78. This was further supported by the
observations that human recombinant GRP78 interfered with the binding of rfhSP-D to
anti-SP-D polyclonal antibodies; GRP78 also significantly inhibited the binding of
recombinant full-length human SP-D with a monoclonal antibody specific to the CRD in
a dose-dependent manner. We conclude that the interaction with rfhSP-D is likely to
interfere with the pro-survival signaling of GRP78.
Keywords: surfactant protein D, GRP78, interactome analysis, prostate cancer, apoptosis, signaling,
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Surfactant protein D (SP-D) recognizes an array of carbohydrate
moieties present on the microbial surfaces (1, 2). SP-D is a
hydrophilic glycoprotein; its primary structure contains N-
terminal region with cysteine residues, a triple-helical collagen
domain, an a-helical coiled-coil neck domain, and a C-terminal
C-type (calcium-dependent) lectin or carbohydrate recognition
domain (CRD). Four SP-D trimeric subunits assemble as a
cruciform dodecamer, and their further oligomers appear as fuzzy
balls under electron microscope (3–5). Pathogens bound to SP-D
get aggregated andopsonized leading to enhancedphagocytosis and
oxidative damage (6). The CRD of SP-D interacts with various self-
ligands as well as receptors such as CD14, Signal Inhibitory
Regulator protein (SIRP)-a, Toll-like receptor (TLR)-2, and TLR-
4 to bring about immune regulation (7, 8).
An important role of SP-D in allergy was noted when a
recombinant fragment of human SP-D (rfhSP-D) composed of
neck and CRD region induced apoptosis in activated eosinophils
of allergic patients (9); this involved p53 upregulation as
demonstrated in rfhSP-D treated AML14.3D10 cells, an
eosinophilic leukemic cell line (10). Subsequently, SP-D was
shown to bind the Epidermal Growth Factor Receptor (EGFR)
on A549 lung cancer cells, inducing cell death (11). Kaur et al.
recently reported that rfhSP-D induced apoptosis in pancreatic
cancer cell lines via TNF-a/Fas pathway irrespective of the p53
status (12). Further, inhibition of TGF-b expression in the
pancreatic cancer cells suppressed their epithelial-to-
mesenchymal transition (EMT) and ability to invade (13). A
significantly reduced expression of SP-D transcripts has been
reported in lung, gastric, and breast cancers, whereas ovarian
cancer tissues express more SP-D. The presence of SP-D
predicted a favorable outcome in lung cancer. Conversely, in
gastric, breast, and ovarian cancers, SP-D expression suggested a
poor prognosis (14).
Reduced expression of SP-D has been observed in the
glandular cells of human prostate cancer tissues. SP-D levels
negatively correlated with Gleason score, a scoring system based
on the cancer cell types and patterns on the tissue sections as well
as tumor volume (15). We recently reported that androgens
regulate SP-D expression in the androgen-sensitive LNCaP
prostate adenocarcinoma cells (16). Importantly, rfhSP-D
specifically induced apoptosis in the tissue explants, primary
tumor cells of patients with metastasized prostate cancer, and the
prostate cancer cell lines (LNCaP, PC3). The rfhSP-D treatment
did not affect the normal prostate epithelial cells (16).
The broad spectrum anti-cancer activity of rfhSP-D is
possibly due to the simultaneous targeting of multiple growth
factors, kinases, transcription factors, and apoptotic pathways
(9–13, 16). Here, we set out to examine the interaction of rfhSP-
D with the membrane proteins of the prostate cancer cell line,
PC3, using Mass Spectrometry-based LC-MS/MS analysis. Based
on the protein−protein interaction (PPI) network analysis of the
interactome proteins, Glucose Regulated Protein of 78 kDa
(GRP78) was found to be an important interactor and was
thus selected for further analysis.Frontiers in Immunology | www.frontiersin.org 2GRP78 is an endoplasmic reticulum (ER) resident chaperone
and is also knownasHSPA5.GRP78acts as anER stress sensor and
is upregulated under stress conditions, for maintaining ER
homeostasis and cell survival. For cellular homeostasis, GRP78
interacts with three ER stress sensor proteins: protein kinase RNA-
like ER kinase (PERK), inositol-requiring kinase 1 (IRE1a), and
activating transcription factor 6 (ATF6). However, under ER stress
conditions, unfolded proteins titrate away GRP78 to activate the
unfolded protein response (UPR) and alleviate cellular stress.
Activated UPR decreases protein influx into the ER and induces
the synthesis of components involved in protein folding to support
cell survival (17). In addition, GRP78 localizes to cell surface
(csGRP78) and operates as a receptor, interacting with various
ligands to induce pro-proliferative, pro-survival, and pro-
apoptotic signalling (18). GRP78 is significantly upregulated in
various cancers due to over stressful microenvironment (17). The
upregulated expression of GRP78 in patients with castration-
resistant prostate cancer has been associated with resistance to
chemotherapy (19, 20). Here, using mass spectrometry, protein-
protein interactome analysis and molecular modelling, we report
GRP78 as a putative receptor for the CRD region of human SP-D.
The interaction between rfhSP-D and GRP78 may interfere with
pro-tumorigenic role of GRP78 in prostate cancer and could be a
plausible mechanism for rfhSP-D-mediated apoptosis of prostate
cancer cells.MATERIALS AND METHODS
Cell Culture
Human prostate cancer cell line, PC3 (androgen independent,
p53-/-) that mimics biochemical changes in advanced prostate
cancer, has been significantly responsive to rfhSP-D induced
apoptosis (16). PC3 cells (ATCC, Rockville, MD, USA) were
grown in RPMI 1640 supplemented with 10% v/v Foetal Bovine
Serum (FBS) and 1% Antibiotics (PenStrep). To achieve
approximately 90% confluence, PC3 cells were incubated in 5%
v/v CO2 at 37°C.
Purification of rfhSP-D
The rfhSP-D (179–355 residues comprised of a functional
homotrimeric lectin domain (236–355 aa residues), followed
by the neck region (203–235 aa residues) and eight Gly-X-Y
repeats from the collagen domain (179–202 aa residues). Using
Escherichia coli BL21 (lDE3) pLysS (Invitrogen), rfhSP-D was
expressed and purified as described earlier (9). The QCL-1000
LAL system (Bio Whittaker Inc., USA) was used to assess the
endotoxin levels. Linearity of the assay was observed in the range
of 0.1–1.0 EU/ml or 0.01–0.1 ng/ml endotoxin. Purified rfhSP-D
contained <4 pg of endotoxin per µg of rfhSP-D.
Isolation of PC3 Membrane Proteins
Interacting With rfhSP-D
PC3 cells (5 × 106/ml) were pre-incubated with in serum-free
RPMI medium containing rfhSP-D (20 µg/ml) and 5 mM CaCl2January 2021 | Volume 11 | Article 600660
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incubated with rfhSP-D to enable isolation of complexes of
rfhSP-D and membrane proteins). Following incubation, the
unbound rfhSP-D was removed along with the medium
followed by a wash with sterile PBS. Then, PC3 cells were
harvested for membrane protein isolation by scrapping in the
wash solution supplied with Mem-PER™ Plus Membrane
Protein Extraction Kit (Thermo Fisher Scientific; #89842).
For the co-immunoprecipitation and pull-down experiments,
10 µg of membrane protein extract, along with bound rfhSP-D,
was combined with 10 µg of polyclonal antibody against human
SP-D (Santacruz) and incubated overnight at 4°C with mixing.
First, Pierce Protein A/G Magnetic beads (Thermo Fisher
Scientific; #88802) were washed three times with TBST wash
buffer. The antigen and antibody mixture was added to 1.5 ml
tube containing pre-washed protein A/G magnetic beads (250
µg) and incubated at room temperature for 2 h on a rotary
shaker. Beads were then separated on a magnetic stand, and the
flow-through was saved for analysis. Beads were washed three
times with the wash buffer and a final wash was given with Milli
Q water. Beads were then resuspended in the elution buffer (0.1
M glycine, pH 2.0) and incubated at room temperature for
10 min with mixing. Beads were separated magnetically and
supernatant containing the target antigen was saved for further
analysis. Low pH was neutralized by adding neutralizing buffer
(1M Tris-HCl, pH 7.5) to the eluate. PC3-derived membrane
protein fraction used for LC-MS/MS analysis was pooled from
five independent pull-down experiments with three
technical replicates.
Western Blot Analysis of Various Fractions
PC3 cells (5 × 106) in serum-free RPMI medium were plated in a
T75 tissue culture flask and pre-incubated with rfhSP-D (20 mg/
ml) for 2 h, as described above. PC3-membrane as well as
cytoplasmic proteins were isolated, as described above, and
analyzed by Western blotting. Lysate proteins (30 mg) were
subjected to 12% v/v SDS-PAGE and electro-transferred onto
PVDF membranes (Pall Corporation, NY, USA). To confirm the
presence of rfhSP-D binding proteins in the two protein
fractions, one of the blot was blocked (3% skimmed milk
powder in TBS, 45 min on a shaker at room temperature),
incubated with rfhSP-D in the presence of CaCl2 or EDTA (2 h at
37°C), and probed with primary rabbit anti-human SP-D
polyclonal conjugate (overnight at 4°C) and secondary goat
anti-rabbit Horseradish Peroxidase (HRP) conjugate (1 h at
room temperature on a shaker). To confirm the purity of the
two protein fractions, another blot was probed with primary
antibodies against human Prostate-Specific Membrane Antigen
(specific to the membrane protein fraction of prostate cells)
(rabbit monoclonal PSMA antibody; Cell Signalling Technology,
# D7I8E, 1:500) overnight at 4°C, followed by HRP-conjugated
secondary goat anti-rabbit IgG antibodies (diluted 1:6000) (1 h
at room temperature on a shaker). The blots were developed
using the enhanced chemiluminescent (ECL) Kit (Millipore,
USA). The blot images were captured using the Syngene
(Chem Genius).Frontiers in Immunology | www.frontiersin.org 3Immune-Depletion of Proteins From
Membrane Fraction
Membrane proteins in the eluate were concentrated using 3 K
filters (Millipore, MA, USA) and then subjected to IgG depletion
using Multiple Affinity Removal System Spin Cartridge, HSA/
IgG (Agilent, CA, USA), following the manufacturer’s
instruction. A buffer exchange followed using Amicon Ultra-
0.5 (3K) device in PBS. Total protein was estimated by Bradford
assay, followed by SDS-PAGE analysis to assess the profile of cell
lysate, and membrane fraction with rfhSP-D treatment after
immune-depletion.
To confirm the presence of rfhSP-D in the two protein
fractions (20 mg), the supernatant of pull-down fraction (5 mg),
flow-through of pull-down fraction (5 mg), eluate of pull-down (5
mg), and flow-through containing IgG after immune-depletion (5
mg) were separated via 12% v/v SDS-PAGE and electro-
transferred to PVDF membranes. Then, the membrane was
blocked and incubated with the rabbit anti-human SP-D
polyclonal antibodies (overnight at 4°C) and secondary
goat anti-rabbit HRP conjugate (1 h at room temperature).
The blot was developed using the enhanced chemiluminescent
(ECL) Kit (Millipore, USA). Image was acquired by Syngene
(Chem Genius).
Lys-C/Trypsin Digestion
Eluates of the five individual pull-down experiments were diluted
in ammonium bicarbonate buffer (TEABC; Sigma) to a final
volume of 100 ml, followed by reduction using 10 mM
dithiothreitol (DTT) for 20 min at 60°C. Once the proteins
came to room temperature, they were alkylated (20 mM
Iodoacetamide; Merck) for 10–15 min at room temperature in
the dark. The proteins were digested with 1 mg of Lys-C for 3–4 h
at room temperature, followed by digestion with 2 mg of trypsin
overnight at 37°C. Enzyme activity was terminated with 1% v/v
formic acid. Peptides were fractionated via C-18 columns and
eluted with a buffer comprising acetonitrile (40%) and formic
acid (0.1%). Fractionated peptides were lyophilized on a
SpeedVac (30 min at 45°C) and then solubilized in 0.1%
formic acid prior to LC-MS/MS analysis.
Mass Spectrometry
Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher
Scientific), connected with an Easy-nLC II nanoflow liquid
chromatography system (Thermo Fisher Scientific), was used
for peptide analysis. A trap column (75 µm × 2 cm, Magic-C18-
AQ material 5 µm, 100 Å) was used to enrich peptides. The
peptides were separated at a flow rate of 30 ml/min on a 20 cm
long column of 5 µm Magic-C18-AQ (Michrom Bioresources,
Inc., Auburn, CA, USA) using a gradient of 8–30% solvent B
(90% acetonitrile in 0.1% formic acid) over 103 min for a
120 min run. Mass spectrometry data were collected at a
resolution of 120,000 in a range of 350–1,600 m/z. The highly
intense ions with charge state >2 were isolated in 3 s cycle and
subjected to HCD fragmentation with 32% normalized collision
energy. These fragmented ions were sensed at a resolution of
15,000 at 200 m/z. The limit of dynamic exclusion was fixed atJanuary 2021 | Volume 11 | Article 600660
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times were 50 ms for MS and 75 ms for MS/MS. The automatic
gain control targets were 4 × 105 for MS and 1 × 105 for MS/MS.
Identification of Peptides and Proteins
From Database
The uninterpreted MS/MS data from the complete LC-MS/MS
run was subjected to a search in the database (Human RefSeq
protein database). The search algorithm used was SEQUEST, and
the platform used was Proteome Discoverer (version 2.1, Thermo
Scientific). Amaximumof twomissed cleavages, carbamidomethylation
at cysteine as fixed and oxidation of methionine as variable
modifications, were included as the search parameters. Mass
tolerance of monoisotopic peptide was set at 10 ppm and the MS/
MS tolerance was limited to 0.02 Da. At the PSM as well as the
protein level, the false discovery rate of 1% was set. MS data has
been submitted to the ProteomeXchange Consortium (http://
www.proteomexchange.org) via the PRIDE partner repository
(dataset identifier PXD008098).
Ingenuity Pathway Analysis
Proteins identified by LC-MS/MS analysis were further analyzed
for their interactions and molecular pathways using Ingenuity
Pathways Analysis (IPA) software (http://www.ingenuity.
com) (21).
Network Analysis
Protein–protein interactions (PPIs) of the rfhSP-D interactome
(347 proteins) were downloaded from STRING v11 (22). Proteins
in the network were scored based on network topological
properties, such as degree of connectivity, clustering coefficient,
betweenness centrality, closeness centrality, and shortest path
using R package igraph (23). The importance of each protein in
the network was assessed based on perturbation and disruption
scores. Perturbation score for each protein reflected the difference
in centrality of network, calculated based on average of clustering
coefficient, betweenness centrality, and closeness centrality after
deletion of a protein (24). Disruption score of each protein was
calculated based on average increase in shortest path length of
protein pairs caused by deletion of the protein (25). Proteins were
ranked individually based on hub (degree of connectivity),
perturbation and disruption analysis; the average rank obtained
from the three methods was used for creating the final ranked list.
The top 5% proteins of the rank list were shortlisted and screened
for their expression in prostate glandular cells as per protein atlas
data (26); prostate cancer (C0376358) and metastasis of prostate
cancer (C1282496) using data available in DisGeNET (27); and
role in cancer cell apoptosis and survival as per information in
ApocanD database (28) and IPA.
Protein Docking
The crystal structure of human GRP78 complexed with ADP
(produced in Escherichia coli BL21) (PDB ID: 5E84 Chain A) was
downloaded from PDB (29). O-glycosylation of GRP78 is critical
for its stability, subcellular localization, and anti-apoptotic
function (30). Putative O-glycosylation sites have been identifiedFrontiers in Immunology | www.frontiersin.org 4in GRP78 (Thr85, Thr151, Thr166, Thr184, and Thr203) based on
in vitro immunoprecipitation assays (30). The crystal structure of
GRP78 was glycosylated by addition of five O-linked N-acetyl-
galactosamine (GalNAc) at the putative sites. The glycosylated
structure was generated using CHARMM-GUI web server and
optimized using CHARMm force field (31). Monomeric form of
GRP78 is present in stress induced cells (32); hence, the
monomeric glycosylated structure of GRP78 was blind docked
with crystal structure of CRD domain of active recombinant
fragment of human lung surfactant protein SP-D (PDB
ID:1PW9) using ZDOCK (Biovia, Discovery studio Version
2017) (33, 34). The input parameters for docking were set as
default options. The top 2,000 docked poses generated by ZDock
were re-ranked utilizing detailed electrostatic, van der Waals and
solvation forces by ZRank (35, 36). The top ranked pose based on
ZRank was further analyzed for intermolecular interactions.
Interaction Studies between rfhSP-D/
rFLhSP-D and GRP78 by ELISA
To analyze the rfhSP-D/rFLhSP-D (recombinant full-length
human SP-D; R & D) interaction with GRP78, the study
utilized non-glycosylated version of GRP78 (purified from E.
coli; Cayman, catalog no. 22730) since the O-linked glycosylated
GRP78 specific to cancer cells is a minor fraction of the total
GRP78 (30). Using a direct ELISA, GRP78 (1 µg/ml in PBS) was
coated on microtitre wells overnight at room temperature. Post-
washing (three times with PBST, PBS + 0.05% Tween 20), the
wells were incubated with 1% w/v BSA in PBS for 1 h at room
temperature to block the additional sites. After extensive
washing, rfhSP-D (1 µg/ml in PBS buffer) was added to the
wells with and without 5 mM CaCl2, or EDTA (10 mM). Bound
rfhSP-D was probed with primary rabbit anti-human SP-D
polyclonal antibodies (1 h at 37°C) and secondary goat anti-
rabbit HRP conjugate (1 h at 37°C), or with biotinylated Human
SP-D detection antibody (500 ng/ml; Duoset SP-D ELISA kit, R
& D Systems, USA) (1 h at room temperature with shaking) and
Streptavidin-HRP conjugate (1:200; 45 min at room temperature
with shaking).
The ability of GRP78 to bind rfhSP-D and block its binding to
rabbit anti-SP-D polyclonal antibodies was analyzed by coating
rfhSP-D (1 µg/ml in PBS) in duplicates, followed by blocking and
incubation with GRP78 (1 µg/ml in PBS). The wells were then
probed with primary rabbit anti-human SP-D polyclonal
antibodies and secondary goat anti-rabbit HRP conjugate.
The ability of GRP78 to bind rFLhSP-D and block its binding to
anti-SP-Dmonoclonal antibody was analyzed by a sandwich ELISA
(Human SP-D Duoset ELISA kit). Human SP-D capture antibody
was coated (2 µg/ml) overnight at room temperature. After washing,
the wells were incubated with 1% w/v BSA in PBS for 1 h at room
temperature to block the unoccupied sites. The wells were then
incubated with 5 ng/ml of rFLhSP-D (116 × 10−3 nM) and
increasing concentrations of human recombinant GRP78 from 5
ng/ml (70 × 10−3 nM) up to 20 ng/ml (280 × 10−3 nM) (1 h at 37°C),
and probed with Human SP-D detection antibody (500 ng/ml) (1 h
at room temperature with shaking). After washing, the wells were
incubated with Streptavidin-HRP conjugate (1:200) (45 min at
room temperature). Color was developed using a substrateJanuary 2021 | Volume 11 | Article 600660
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B (Tetramethylbenzidine); optical density was measured at 450 nm
using an ELISA plate reader (Beckman Coulter).
Statistical Analysis
The data obtained for various experiments were analyzed for
statistical significance and graphical representation using
GraphPad PRISM ver6.0 (GraphPad Software Inc., San Diego,
CA). To compare the untreated and treated groups, the
unpaired t-test was used. Data have been represented as mean ±
SD. The p values less than 0.05 showed that the findings were
statistically significant.RESULTS
Isolation of Membrane Proteins From
rfhSP-D Pre-Treated PC3 Cells
To investigate the rfhSP-D interactome in PC3 cells, we
performed co-immunoprecipitation and pull-down assays
using polyclonal antibodies to rFLhSP-D, followed by immune-
depletion of abundant proteins (HSA/IgG) and LC-MS/MS
analysis (workflow scheme shown in Figure 1).Frontiers in Immunology | www.frontiersin.org 5The protein profile of the membrane as well as cytosolic
fractions isolated after rfhSP-D pull-down assay using rfhSP-D-
treated PC3 cells was distinct, as revealed by SDS-PAGE (Figure
2A). Figures 2B(i) and C(i) represent protein bands electro-
transferred to PVDF membrane, stained with Ponceau dye and
used as loading control. Ligand blotting of the membrane and
cytosolic protein fractions with rfhSP-D showed presence of
rfhSP-D binding proteins in both the fractions [Figure 2B(ii)].
Western blot analysis showed significant enrichment of Prostate-
specific Membrane Antigen (PSMA) in the membrane fraction
in comparison to cytosolic fraction [Figure 2B(iii)]. Figure 2C
(ii) shows the Western blot of isolated PC3 cell membrane
proteins after 2 h incubation with rfhSP-D and subsequent
fractions, using anti-human SP-D polyclonal antibody.
Following 2 h incubation, the unbound rfhSP-D was removed
along with the medium, followed by a wash with sterile PBS.
Hence, only the ligand-bound rfhSP-D is expected to be present
in the protein fractions analyzed. Native SP-D protein levels in
the cell culture supernatants of PC3 cells (1 × 106/ml–3.2 µg of
total protein/µl), as evaluated by ELISA, were found to be 220 ±
21 pg/ml, indicating approximately 68.75 pg of SP-D/mg of
protein (16). Expected molecular weight of rfhSP-D is
approximately 20 kDa and that of full-length SP-D is ~43 kDaFIGURE 1 | Work flow and data analysis. PC3 cells were incubated with rfhSP-D for 2 h at 37°C. Cells were then subjected to membrane protein extraction. The
isolated PC3 cell membrane proteins were incubated with polyclonal anti-human SP-D antibody for obtaining rfhSP-D-bound membrane proteins (pull-down assay).
The rfhSP-D interacting membrane proteins were subjected to immunodepletion. The immunodepleted rfhSP-D-bound PC3 cell membrane proteins were subjected
to LC-MS/MS analysis. The identified rfhSP-D interacting membrane proteins were further examined using Network and Ingenuity Pathways Analysis. HSPA5/GRP78
was identified as a potential binding/interacting partner of rfhSP-D and was confirmed by in silico analysis (molecular docking) and in vitro studies (Direct and
competitive ELISA).January 2021 | Volume 11 | Article 600660
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rfhSP-D are known to exist as oligomers; post-translationally
modified and proteolytically truncated forms of native SP-D
have also been reported (37–39). Therefore, multiple bands
representing various forms of native human SP-D from the
PC3 cells and ligand-associated rfhSP-D could be seen in the
Western blot.
The lanes 2, 3, 4 are PC3 cell entire protein (PC3), cytosolic
(PC3-C), and membrane protein (PC3-M) (20 µg). Owing to the
low amounts of native SP-D and rfhSP-D in the cell lysate and
fractions, the anti-human SP-D antibody could detect multiple
faint bands, suggesting presence of different oligomeric and
truncated forms. Lane 5 was anti-human SP-D antibody pull-
down eluate (rfhSP-D-bound fraction of PC3-M) (7 µg) that
showed the presence of oligomeric forms of SP-D and rfhSP-D.
Lane 6 was the supernatant of pull-down eluate (rfhSP-D-
unbound fraction of PC3-M) (5 µg), and therefore, was expected
to show minimal amounts of rfhSP-D. Lane 7 (5 µg) was the
immune-depleted, rfhSP-D-bound fraction of PC3-M (flow-
through of Multiple Affinity Removal System Spin Cartridge,
HSA/IgG) that showed the absence of native SP-D and rfhSP-D.
Native SP-D and rfhSP-D can bind various classes of
immunoglobulins, including IgG, IgM, IgE and secretory IgA,
via its CRD region in a calcium-dependent manner (40). Thus,Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 600666after immune-depletion of abundant proteins IgG/HSA and
interacting proteins (including rfhSP-D and native SP-D) from
the rfhSP-D-bound fraction of PC3-M, the flow-through did not
contain rfhSP-D and native SP-D. This was further corroborated
by the LC-MS/MS analysis of this fractionwherein the native SP-D
and rfhSP-Dwere not detected. It is important to note that some of
the rfhSP-D-binding proteinsmayhave also beenmissed out in the
pull-down eluate. Lane 8 is the IgG/HSA and interacting proteins
enriched eluate of rfhSP-D-bound fraction of PC3-M (eluate from
Multiple Affinity Removal System Spin Cartridge, HSA/IgG) (20
µg). This fraction, as expected, showed different oligomeric and
truncated forms of native SP-D and rfhSP-D. Lane 9 was purified
rfhSP-D (0.5 µg) loaded as a positive control.
IgG and other abundant proteins in the membrane fraction
were immune-depleted using Multiple Affinity Removal Spin
Cartridge HSA/IgG as they can potentially mask the detection of
low abundant proteins on LC-MS/MS analysis. SDS-PAGE
profile showed enrichment of other proteins following
immune-depletion of IgG and HSA (Figure 3).
Identification of the Membrane Proteins
of PC3 Cells Interacting With rfhSP-D
Mass spectrometric analysis (LC-MS/MS) of PC3 cell membrane
fraction, treated with rfhSP-D, led to the identification of a totalA B
C
FIGURE 2 | Isolation and characterization of the proteins in PC3 cell lysate. (A) Visualization of isolated protein fractions. Membrane Protein (PC3-M) and Cytosolic
Protein (PC3-C) from PC3 cells by Coomassie Brilliant Blue dye gel staining. (B) Presence of rfhSP-D interacting partners in the isolated protein fractions PC3-C and
PC3-M (Far-Western/ligand blotting). (i) electro-transferred to PVDF membrane stained with Ponceau dye used as loading control. (ii) Lanes 1, 2: Incubated with
rfhSP-D and CaCl2; Lane 3s, 4: Incubated with rfhSP-D, CaCl2 and EDTA; Lanes 5, 6: Incubated with Secondary goat anti-rabbit HRP conjugate alone (antibody
control). (iii) Prostate specific Membrane Antigen (PSMA) specifically expressed in isolated PC3 cells membrane protein fraction. (C) rfhSP-D was not detected in the
immune-depleted, rfhSP-D bound fraction of PC3-M and was present in the IgG/HSA and interacting proteins enriched eluate of rfhSP-D bound fraction of PC3-M.
(i) Various electrophoresed protein fractions were electro-transferred to PVDF membrane and stained with Ponceau dye to reveal the profile. (ii) Lane 1: Ladder;
Lane 2: Entire PC3 cell protein (PC3) (20 mg); Lane 3: Cytosolic protein fraction of rfhSP-D treated PC3 cell (PC3-C) (20 mg); Lane 4: Membrane protein fraction of
rfhSP-D treated PC3 cell (PC3-M) (20 mg); Lane 5: rfhSP-D bound fraction of PC3-M (7 mg); Lane 6: rfhSP-D unbound fraction of PC3-M (5 mg); Lane 7: Immune-
depleted rfhSP-D bound fraction of PC3-M (flow-through of Multiple Affinity Removal System Spin Cartridge, HSA/IgG) (5 mg); Lane 8: IgG/HSA and bound proteins
enriched eluate of rfhSP-D bound fraction of PC3-M (Eluate from Multiple Affinity Removal System Spin Cartridge, HSA/IgG) (20 mg); Lane 9: rfhSP-D (0.5 mg).
Expected molecular weight of monomeric rfhSP-D is approximately 20 kDa, and it can exist as a dimer and trimer. MW of native SP-D is 43 kDa under reducing
conditions, and glycosylated forms of SP-D are with an mw of 50–58kDa. Proteolytically truncated forms of native SP-D appear at ~25kDa.0
Thakur et al. Interactome Studies Identify a SP-D Receptorof 672 proteins, out of which 347 proteins were detected with ≥2
unique peptides, each with at least two peptide-spectrum
matches (PSMs) and were considered as rfhSP-D interactome
(Supplementary File S1). For each protein, accession, gene
symbol, description, protein name, molecule weight, sequence
coverage (%), PSMs, unique peptides and Score Sequest HT:
Sequest HT have been provided (Supplementary File S2). Based
on the PSM values from LC-MS/MS data, GRP78 (HSPA5; PSM
value: 72) was the top ranked protein in the list of 347 proteins
identified in the rfhSP-D interactome. Interestingly, six more
members of the heat-shock protein (HSP) family that are
reported to be involved in regulation of apoptosis of cancer
cells, namely HSP90AB1 (PSM value: 55), HSPA8 (PSM value:
54), HSP90AA1 (PSM value: 54), HSPA1B (PSM value: 39),
HSP90B1 (PSM value: 36), and HSPD1 (PSM value: 35), were
listed among the first fifteen proteins. Some of the reported SP-D
receptors such as DEFA1 (Human Alpha Defensin 1), CALR
(Calreticulin), C1QBP (C1q receptor, gC1qR), and A2ML1 (a2-
macroglobulin-like protein 1), were also present in the identified
interactome (Supplementary File S1) (2, 6). Identification of
these putative SP-D receptors validated the interactome analysis.
As discussed above, the proteins identified from the LC-MS/MS
analysis did not include SP-D. Therefore, SP-D was added to the
list of 347 proteins for subsequent bioinformatics analysis in
order to decipher the networks and protein–protein interactions.
Pathway Analysis of the rfhSP-D
Interactome
The rfhSP-D interactome [348 proteins, 347 identified proteins +
SP-D (P35247)] was analyzed by ingenuity pathway analysis
(IPA) for associated biological functions, canonical pathways,
and networks. Our network analysis revealed novel signaling
proteins that are likely to interact (directly/indirectly) withFrontiers in Immunology | www.frontiersin.org 7rfhSP-D and/or regulate its associated networks (Figure 4A).
The binding partners of rfhSP-D identified herein were also
classified on the basis of their molecular and cellular functions
(Figure 4C). Cell Death and Survival, Cellular Compromise,
Protein Synthesis, Post-Translational Modification and Protein
Folding emerged as significant categories in the rfhSP-D binding
proteins. IPA revealed that top five canonical signaling pathways
significantly associated with rfhSP-D (p-value < 0.001; Figure
4B). Protein Ubiquitination Pathway was the top-ranked (p
value = 1.26E-13) canonical pathway that included GRP78
(HSPA5) and SFTPD.
IPA analysis further revealed the involvement of several
transcription factors such as FOXM1, JUND, FOXA2, JUNB,
CEBPA, JUN, CEBPB, and FOS that regulate the expression of
SP-D. The human SP-D gene promoter has a conserved activator
protein-1 (AP-1) element (−109) wherein transcription factors of
the fos and jun families bind (41). Foxm1 regulates transcription
of several genes involved in the surfactant homeostasis and lung
development, including all the four surfactant-associated
proteins-SP-A, SP-B, SP-C, and SP-D (42). CCAAT-enhancer-
binding protein (C/EBP) transcription factors are required for
basal and enhanced SP-D promoter activity, as evident in C/
EBPb cDNA co-transfected H441 cells (43).
Network Analysis of rfhSP-D Interactome
The PPI network of 347 proteins was analyzed for network
parameters (Materials and Methods) to shortlist critical proteins
of the rfhSP-D interactome. 20 proteins (GAPDH, HSPA8,
HSP90AA1, HSPA4, TPI1, ENO1, VCP, CCT2, HSPA5, LCN2,
EEF2, ACTG1, HSPD1, PDIA6, CCT8, S100A7, HSPA9, LCN1,
HSP90AB1, CCT5) were selected and ranked based on
connectivity, perturbation, and disruption scores (Table 1;
Supplementary File S3). 15 of these 20 proteins are known toFIGURE 3 | Protein profile of different fractions of PC3 cells before and after co-immunoprecipitation. Lane 1: Total PC3 cell protein (PC3, 15 µg); Lane 2: Cytosolic
protein fraction of rfhSP-D treated PC3 cells (PC3-C, 20 µg); Lane 3: Membrane protein fraction of PC3 cells (20 µg); Lane 4: Membrane protein fraction of rfhSP-D
treated PC3 cells (PC3-M, 20 µg); Lane 5: rfhSP-D bound fraction of PC3-M (5 µg); Lane 6: Immune-depleted rfhSP-D bound fraction of PC3-M (7 µg); Lane 7: IgG/
HSA and bound proteins enriched eluate of rfhSP-D bound fraction of PC3-M (20 µg).January 2021 | Volume 11 | Article 600660
Thakur et al. Interactome Studies Identify a SP-D Receptorbe associated with prostate cancer, 13 with prostate cancer as well
as apoptosis, and only two (HSP90AA1, HSPA5) are known to
be associated with metastasis of prostate cancer (Figure 5; Table
2; Supplementary File S2). Of the two, HSPA5 is known to be
expressed in prostate glandular cells as per the protein atlas;
therefore, it was selected for further in silico and in vitro
interaction studies. A summary of the network analysis of
rfhSP-D interactome is represented as a Venn diagram (Figure
5). HSPA5 or GRP78, a chaperone expressed on cell surface of
cancer cells only, is known to be associated with malignancy,Frontiers in Immunology | www.frontiersin.org 8development of castration-resistant prostate cancer, and
resistance to chemotherapy. GRP78 seems to act upstream of
PI3K/Akt; monoclonal antibody against GRP78 suppresses pAkt
expression, suggesting promotion of apoptosis (44).
In Silico Validation of the Interaction of
SP-D With GRP78
From the proteomic analysis, GRP78 was the top-ranked protein of
the rfhSP-D-PC3 membrane interactome and hypothesized to be
involved in the apoptosis signaling by binding to rfhSP-D molecule.
In silicomolecular docking was performed to validate this hypothesis.
The top ranked pose (Zrank = −131.3) from blind docking of rfhSP-
D and GRP78 revealed that CRD of SP-D can bind with GRP78 via
the substrate binding domain of GRP78 (Figure 6; Table 3).
In Vitro Verification of Interaction Between
rfhSP-D/rFLhSP-D and GRP78
To examine GRP78 binding to rfhSP-D, we carried out a direct
ELISA with recombinant GRP78 and rfhSP-D that was probed
using the polyclonal and monoclonal antibodies to SP-D (Figure
7A). Polyclonal antibodies could detect rfhSP-D (1 µg/ml, 0.232
nM)bound to coatedGRP78 (1 µg/ml, 0.280nM) in the presence of
Ca2+. However, EDTA did not significantly inhibit the binding,
indicating a protein–protein interaction. Monoclonal anti-human
SP-D antibodies recognizing peptides NEAAFLSMTDSK
(positions 308–319) and SAAENAALQQLVVAK (positions 293–
307) that are located in the CRD region of SP-D (45), could not
detect the rfhSP-Dbound tocoatedGRP78, suggesting involvement
of the CRD region of rfhSP-D in binding to GRP78.
To evaluate if GRP78 binding can interfere with the
interaction of rfhSP-D and polyclonal antibodies, a direct
ELISA was carried out using rfhSP-D coated on the microtitre
wells, followed by GRP78 as the ligand and probed with
polyclonal antibodies. Minimal binding of polyclonal anti-A B
C
FIGURE 4 | Ingenuity pathway analysis-based rfhSP-D networks in metastatic prostate cancer cells. (A) Protein network obtained using Ingenuity Pathway Analysis
(IPA) demonstrating interactions of rfhSP-D with proteins involved in the Cellular Compromise, Dermatological Diseases and Conditions, Organismal Injury and
Abnormalities. (B) Canonical Pathway analysis categorizing rfhSP-D interacting proteins into different pathways such as Protein Ubiquitination Pathway, unfolded
protein response, Aldosterone Signaling, Glycolysis I, and Gluconeogenesis (I) (C) Upstream analysis of rfhSP-D interactome segregated proteins in the following
pathways—Cell Death and Survival, Cellular Compromise, Protein Synthesis, Post-Translational Modification, and Protein Folding.TABLE 1 | Shortlisted proteins from the rfhSP-D interactome and their ranks as per









GAPDH 1 1 1 1 1
HSPA8 2 2 3 2.33 2
HSP90AA1 3 3 13 6.33 3
HSPA4 4 6 9 6.33 3
ENO1 6 4 16 8.67 4
TPI1 7 19 2 9.33 5
VCP 11 12 5 9.33 5
CCT2 5 10 15 10 6
HSPA5 12 13 6 10.33 7
LCN2 6 18 8 10.67 8
EEF2 18 8 7 11 9
ACTG1 15 9 10 11.33 10
HSPD1 8 16 12 12 11
PDIA6 16 7 14 12.33 12
CCT8 9 11 17 12.33 12
S100A7 17 20 4 13.67 13
HSPA9 13 17 11 13.67 13
LCN1 19 5 19 14.33 14
HSP90AB1 10 15 20 15 15
CCT5 14 14 18 15.33 16January 2021 | Volume 11 | Article 600660
Thakur et al. Interactome Studies Identify a SP-D Receptorhuman SP-D antibody to rfhSP-D (1 µg/ml i.e. 0.232 nM) was
observed due to the blocking/masking of antibody-recognized
domains by GRP78 (1 µg/ml i.e. 0.280 nM).
To examine if GRP78 binding to rFLhSP-D (recombinant
full-length human SP-D) is via CRD domain, we carried out a
competitive sandwich ELISA (R&D ELISA kit) using theFrontiers in Immunology | www.frontiersin.org 9monoclonal anti-human SP-D antibody. The assay detected
rFLhSP-D from 0.115 to 10 ng/ml in a linear standard curve
(Figure 7B). rFLhSP-D bound GRP78 in a dose-dependent
manner leading to dose dependent inhibition of binding of
monoclonal anti-SP-D detection antibody (Figure 7C). GRP78
(20 ng/ml i.e. 281 × 10−3 nM) on binding to rfhSP-D (5 ng/ml i.e.
116 × 10−3 nM) showed approximately 57.15% inhibition of
binding to monoclonal anti-human SP-D antibodies. Thus,
GRP78 interfered with the interaction between rFLhSP-D and
monoclonal anti-human SP-D antibody, suggesting that CRD of
rFLhSP-D is likely to be involved in its binding to GRP78.DISCUSSION
To delineate the underlying mechanisms of the anti-prostate
cancer activity of rfhSP-D, we used a pull-down strategy to
unravel the rfhSP-D interactome from the membrane fraction of
the metastatic prostate cancer cell line, PC3. A high-throughput
proteomic work flow led to the identification of 347 membrane
proteins with ≥2 unique peptides, each with ≥2 PSMs. Based on
the PPi network properties such as connectivity, perturbation,
and disruption scores, 20 proteins were selected, including
GRP78 that probably interacted directly or indirectly with
rfhSP-D. The interaction between rfhSP-D and GRP78 was
validated by in silico and in vitro experimental analysis.
We recently reported a differentially increased binding of
rfhSP-D to the metastatic prostate cancer cells and induction of
the apoptosis (16). The membrane interactome of PC3 cells,
treated with rfhSP-D, showed involvement of several heat-shock
protein family members such as GRP78 (HSPA5), HSP90AB1,
HSPA8, HSP90AA1, HSPA1B, HSP90B1, and HSPD1, as
previously reported (46). Elevated levels of HSPs have beenFIGURE 5 | Network analysis of rfhSP-D binding proteins of PC3 cells. Network representation of 20 shortlisted proteins from network analysis; pie of node
represents the analysis (hub, perturbation, disruption). Overlaying Venn represents proteins known to be associated with prostate cancer, prostate cancer
metastasis, apoptosis, and expressed in prostate cells.TABLE 2 | Shortlisted proteins from the network analysis of rfhSP-D interactome
with reported expression in prostate, prostate cancer, prostate cancer metastasis









GAPDH ✓ ✓ x ✓
HSPA8 ✓ ✓ x ✓
HSP90AA1 x ✓ ✓ ✓
HSPA4 ✓ ✓ x ✓
TPI1 ✓ x x x
ENO1 ✓ ✓ x ✓
VCP ✓ ✓ x ✓
CCT2 ✓ ✓ x ✓
HSPA5 ✓ ✓ ✓ ✓
LCN2 x ✓ x ✓
EEF2 ✓ ✓ x ✓
ACTG1 ✓ ✓ x x
HSPD1 ✓ ✓ x ✓
PDIA6 ✓ x x x
CCT8 ✓ x x x
S100A7 x ✓ x ✓
HSPA9 ✓ ✓ x ✓
LCN1 x x x x
HSP90AB1 ✓ ✓ x ✓
CCT5 ✓ x x ✓aAs per data available in protein atlas; bas per data available in DisGeNET; Cas per data
available in ApocanD and IPA.
*Association with apoptosis pathway.January 2021 | Volume 11 | Article 600660
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GRP78 and HSP90AA1 were present in the databases of
prostate cancer (C0376358), metastasis of prostate cancer
(C1282496) using data available in DisGeNET, and have a
significant role in cancer cell apoptosis and survival as per
information in ApocanD database and IPA. However,
HSP90AA1 is not expressed in the prostate glandular cells as
per protein atlas data (26). In addition, it does not relocate to the
cell membrane like GRP78 in prostate cancer and is rather
secreted extracellularly (47). Interestingly, the ‘Cellular and
Molecular Pathway’ analysis of rfhSP-D interactome listed
GRP78 and SP-D together in the top ranked ‘Cell Death and
Survival’ category. Hsp90AB1 induces angiogenesis in the
hepatocellular carcinomas, promotes EMT in gastric cancer, and
its upregulated expression is implicated in metastasis and
differentiation of lung cancer (48–50). HSPA1B and HSPA8 have
shown involvement in the apoptotic signaling. Proteomics analysis
of endometrial carcinoma tissue identified HSPA8 as the most
upregulated candidate, and siRNA-mediated inhibition of HSPA8
significantly downregulated cell proliferation and promoted cell
apoptosis in RL-95-2 and HEC-1B, two endometrial cancer cell
lines (51). siRNA targetingHSPA1Bgene inhibited proliferation of
HeLa, MCF-7, PC-3, HuH-7, and gastric cancer SGC-7901 cells,
while the non-tumorigenic HBL-100 mammary cells were not
affected adversely (52). HSP90B1, a stress-inducible chaperone
protein, significantly reduced the cell proliferation and survival of
the malignant cells (53). In comparison with the benign prostate
samples, HSPD1/E1 Complex is over-expressed in prostate cancer
lesions and in carcinomas (54).Frontiers in Immunology | www.frontiersin.org 10GRP78, also called heat-shock protein 5 (HSPA5), is a member
of theHSP70 superfamily, andhas a critical role in the regulationof
the unfolded protein response (UPR) via appropriate protein
folding, inhibiting aggregation of newly-made proteins, and
regulating the stimulation of transmembrane sensors in the
endoplasmic reticulum (ER) (55). Expression of GRP78 is
significantly enhanced in various cancers, and is linked with the
prostate cancer malignancy, metastasis and acquisition of
resistance to chemotherapy (56). Prostate tumorigenesis was
potently arrested in bi-allelic conditional knockout mice for both
GRP78 and PTEN (57). Environment of the fast-growing solid
tumors is marked with increased hypoxia, and reduced nutrients
and acidosis, leading to UPR and increased GRP78 expression.
GRP78directly interactedwith apoptotic pathway intermediates to
block caspase activation, and eventually led to increased cell
survival (58–60).
GRP78 has been primarily localized to the ER owing to the
presence of the KDEL-retention motif, although a minor
proportion of GRP78 evades the ER-retention mechanism and
reaches the cell surface to promote cell survival (61). Proteomics
of the membranes of various tumor cells unravelled a number of
heat-shock chaperones and glucose-regulated proteins, including
GRP78 (62). These reports are in coherence with our observation
of GRP78 to be in the membrane proteome of PC3 cells.
Additionally, Thapsigargin, a mediator of ER stress, is involved
in surface localization of GRP78 in 293T, HeLa, and MCF-7 cell
lines (63). Furthermore, an increased GRP78 expression can lead
to its translocation to the membrane even when there is no ER
stress (64).A B
C
FIGURE 6 | In silico validation of the interaction of rfhSP-DSP-D with GRP78. (A) Top-ranked docked pose of rfhSP-D (CRD) depicted in cyan and GRP78 (SBD)
depicted in pink; (B) N-acetyl galactosamine (GalNAc) modeled at Thr203 of GRP78 (pink) was found to be within 10 Å radius of residues of rfhSP-D (cyan) in the
docked complex; (C) residues involved in intermolecular interactions of GRP78 (pink) and rfhSP-D (cyan).January 2021 | Volume 11 | Article 600660
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Frontiers in Immunology | www.frontiersin.org 11Membrane GRP78 may bind to a2-macroglobulin (a2-M),
tumor differentiation factor, and vaspin via its substrate binding
domain and induce AKT/PI3K pro-survival pathway (65–71).
Peptides targeting membrane GRP78 induce selective tumor cell
death. Antibody ligation to cell-surface GRP78 slowed growth
rate in prostate cancer cells and blocked PI3K/AKT signaling
(72). The predicted involvement of the substrate binding domain
of GRP78 in the interaction with rfhSP-D suggested that SP-D
may interfere with these pro-survival mechanisms. Thus, the
rfhSP-D induced inhibition of PI3K/Akt pathway leading to
apoptosis of prostate cancer cells could be plausibly mediated
by GRP78 (16).
Case–control studies of lung cancer patients have revealed that
the circulating SP-D levelsmay predict susceptibility to lung cancer
(73, 74). The collagen and CRD regions of SP-D play different but
vital roles in the immunesurveillance.TheCRDregionmediates the
pattern recognition function, while the collagen region remains
important for the signaling interaction via Calreticulin–CD91
complex. However, studies using rfhSP-D have revealed that the
homotrimeric neck and CRD region are endowed with virtual self-
sufficiency inmany aspects (6). Several lines of evidence suggest the
importance of CRD region of SP-D in its biological activity, e.g.
CRD region interfered with the EGF and EGF receptor (EGFR)
interaction, causing downregulation of the EGF induced signaling
in A549 cell line (11). EGF–EGFR interaction results in increased
epithelial tumor cell proliferation, angiogenic differentiation, and
invasive capability, leading to increased probability of metastasis.
Recently, it was demonstrated that SP-D interacted with the EGFR

































FIGURE 7 | Recombinant human GRP78 binds CRD domain of rfhSP-D/rFLhSP-D. (A) Recombinant human GRP78 showed direct binding to rfhSP-D in presence
of CaCl2 (Bar 1) and was not inhibited by (Bar 2). Monoclonal antibodies against the CRD domain of rfhSP-D did not recognize rfhSP-D bound to recombinant
human GRP78 (Bar 3). Recombinant human GRP78 did not interact with rfhSP-D bound to monoclonal antibodies specific to the CRD domain of SP-D (Bar 4). The
data presented are the mean ± S.D from independent experiments conducted three times. *p < 0.05 vs. Bar 1. (B) Standard curve of the rFLhSP-D (0–10 ng/ml)
from Duoset SP-D ELISA kit, R & D Systems. (C) The rFLhSP-D binding to anti-human SP-D capture antibody (Duoset) was significantly inhibited in the presence of
GRP78 in a dose-dependent manner. The GRP78 concentration ‘0’ in the graph represents the control where only buffer was coated and the experiments were
conducted three times, *p < 0.05 vs. control. **p<0.01 vs. control, ns is non significant.January 2021 | Volume 11 | Article 600660
Thakur et al. Interactome Studies Identify a SP-D Receptorits interactionwith EGF (75). The interaction of SP-D and rfhSP-D
with eosinophilic leukemicAMLcellswas alsomediatedbyCRD(9,
10). Kaur et al. proposed that the CRD region of SP-D is involved in
binding to target ligand on the pancreatic cancer cell
surface via protein–protein interaction (13). Our results
demonstrate that the interaction of rfhSP-D with GRP78 also
involved the CRD domain, which could be relevant in the
induction of apoptosis in cancer cells.
O-glycosylation of GRP78 is critical for its anti-apoptotic
function (76). Blind docking of the crystal structures of active
rfhSP-D and monomeric glycosylated structure of GRP78
revealed that the CRD of rfhSP-D can bind GRP78 via the
substrate binding domain of GRP78. Thus, our in silico and in
vitro analyses validate the interaction between rFLhSP-D/rfhSP-
D and GRP78 via CRD region, substantiating GRP78 as binding
partner of SP-D and may potentially be a novel intermediary in
SP-D mediated innate immune surveillance against prostate
cancer. The therapeutic relevance of SP-D-GRP78 interaction
may be further explored using in vivo studies with knockout mice
models bearing prostate cancer.DATA AVAILABILITY STATEMENT
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